Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Topic Tracks*:

Organ Site Tracks*:

Showing session: reset

Can the Challenge of NSCLC Resistance Be MET or Will We Not MEK It?

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 4 of 4
Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations
Shun Lu
Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
Lecia Sequist
Massachusetts General Hospital, Boston, MA, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study
Suresh S Ramalingam
Emory Univ. Winship Cancer Inst., Atlanta, GA, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
Discussant
Roy S Herbst
Yale Cancer Ctr., New Haven, CT, United States
from AACR Annual Meeting 2019 on March 31, 2019 3:00 PM-5:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 4 of 4